CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 30, 2026-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on Sept. 30, 2026 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s
Patients treated with delandistrogene moxeparvovec at ages 8-12 demonstrated durable and clinically meaningful benefits across the North Star Ambulatory Assessment and timed function measures over 2 years compared to a well-matched external control group Separate findings in children treated at
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 25, 2026-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present new data from its portfolio of treatments for Duchenne muscular dystrophy at the 31 st Annual Congress of the World Muscle Society
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 24, 2026-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present new data at the 27 th Annual Neuromuscular Study Group (NMSG) Scientific Meeting, taking place Sept.
Recipients include 20 individuals living with Duchenne and five siblings of individuals living with the condition Now in its ninth year, program has awarded more than 150 scholarships CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 8, 2026-- Sarepta Therapeutics, Inc.
Entre los destinatarios se incluyen 20 personas con Duchenne y cinco hermanos de personas con la enfermedad Ahora en su noveno año, el programa ha otorgado más de 150 becas CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 8, 2026-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), el líder en medicina genética
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 31, 2026-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Morgan Stanley 24 th Annual Global Healthcare Conference on
New CEO Michael Severino, MD, brings extensive biopharma leadership and a proven track record of advancing innovation, building franchises, and delivering growth Net product revenues for the second quarter 2026 totaled $328.7 million, consisting of $230.6 million of PMO net product revenue and
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 29, 2026-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on July 28, 2026, that were previously approved by its Board of Directors under Sarepta’s 2024 Employment Commencement
– Severino joins Sarepta’s Board of Directors – Doug Ingram to retire from Sarepta CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 27, 2026-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Michael Severino, M.D., as
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 22, 2026-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2026 financial results after the Nasdaq Global Market closes on Wednesday, Aug. 5, 2026. Subsequently, at 4:30 p.m.